Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:awards |
Best Emerging Pharma Company 2020
Excellence in Quality 2021 |
| gptkbp:CEO |
gptkb:Dr._Anirban_Mukherjee
|
| gptkbp:clinicalTrials |
Completed
Ongoing Phase II Phase III Phase I |
| gptkbp:collaborations |
Research Institutions
Universities Healthcare_Providers |
| gptkbp:communityEngagement |
Educational Programs
Health Camps |
| gptkbp:employees |
500+
|
| gptkbp:exportMarkets |
gptkb:Latin_America
gptkb:Southeast_Asia Middle_East |
| gptkbp:financialPerformance |
Profitability
Growing Revenue Market Share Increase |
| gptkbp:focusArea |
Generic_Drugs
|
| gptkbp:foundedIn |
2015
|
| gptkbp:futurePlans |
New Product Development
Expansion into New Markets Increased R&D Investment |
| gptkbp:headquarters |
gptkb:Kolkata,_India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bengal Pharmaceuticals
|
| gptkbp:investmentFocus |
Technology
Manufacturing Facilities R&D |
| gptkbp:market |
gptkb:Asia
Africa Europe |
| gptkbp:operatesIn |
gptkb:India
|
| gptkbp:partnerships |
Various international pharmaceutical companies
|
| gptkbp:patentCitation |
Multiple
Innovative Formulations New_Drug_Delivery_Systems |
| gptkbp:products |
Antibiotics
Cardiovascular Drugs Analgesics Antipyretics |
| gptkbp:regulatoryCompliance |
gptkb:FDA
WHO |
| gptkbp:researchAndDevelopment |
Yes
|
| gptkbp:socialResponsibility |
Disaster Relief Efforts
Health Awareness Programs Environmental Protection Initiatives |
| gptkbp:sustainabilityInitiatives |
Yes
|
| gptkbp:website |
www.bengalpharma.com
|